Outcomes in Patients With VTE by Anticoagulant, BMI ≥50 kg/m2
Recurrent
Venous
Thromboembolism
Major
Bleeding
Composite
Bleeding
Patients (%)
0%
5%
10%
15%
20%
25%
30%
0% (0/10)
0% (0/30)
4% (2/52)
P = .63
0% (0/10)
0% (0/30)
4% (2/52)
P = .63
0% (0/10)
20% (6/30)
15% (8/52)
P = .44
Apixaban
Rivaroxaban
Warfarin
1|2